Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

7.3%

14 terminated/withdrawn out of 191 trials

Success Rate

92.1%

+5.6% vs industry average

Late-Stage Pipeline

39%

75 trials in Phase 3/4

Results Transparency

60%

99 of 164 completed trials have results

Key Signals

1 recruiting99 with results11 terminated

Enrollment Performance

Analytics

Phase 3
75(40.8%)
Phase 2
75(40.8%)
Phase 1
26(14.1%)
N/A
8(4.3%)
184Total
Phase 3(75)
Phase 2(75)
Phase 1(26)
N/A(8)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (191)

Showing 20 of 191 trials
NCT01368588Phase 3Active Not Recruiting

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Role: lead

NCT02635009Phase 2Completed

Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

Role: collaborator

NCT00936390Phase 3Completed

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Role: lead

NCT01546987Phase 3Completed

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Role: lead

NCT00063882Phase 3Completed

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Role: lead

NCT01349322Phase 3Active Not Recruiting

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Role: lead

NCT01730937Phase 3Completed

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Role: lead

NCT01302834Phase 3Completed

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Role: lead

NCT00956007Phase 3Active Not Recruiting

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Role: lead

NCT00980954Phase 3Completed

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Role: lead

NCT07014618Recruiting

Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Role: collaborator

NCT00567580Phase 3Active Not Recruiting

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Role: lead

NCT00922974Phase 2Completed

Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Role: lead

NCT01220583Phase 2Active Not Recruiting

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Role: lead

NCT01753414Phase 2Active Not Recruiting

Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC

Role: lead

NCT01993810Phase 3Active Not Recruiting

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Role: lead

NCT00365105Phase 3Completed

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Role: lead

NCT00981656Phase 2Completed

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Role: lead

NCT00003375Phase 2Completed

Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

Role: lead

NCT00114140Phase 2Completed

Temozolomide and Radiation Therapy in Treating Patients With Gliomas

Role: lead